Lead asset
Programs
RESIST
Treatment-resistant Depression (TRD)
Preclinical
Phase 1
Phase 2/2A
Phase 2B/3
Programs
Psychiatry
Schizophrenia (SCZ)
Genetic subset
Preclinical
Phase 1
Phase 2/2A
Phase 2B/3
Programs
Neuro-disease
Undisclosed
Genetic subset
Preclinical
Phase 1
Phase 2/2A
Phase 2B/3
Programs
Psychiatry
Alcohol Use Disorder (AUD)
Preclinical
Phase 1
Phase 2/2A
Phase 2B/3
Second asset
Programs
Post-Traumatic recovery
Preclinical
Phase 1
Phase 2/2A
Phase 2B/3
Our RESIST Program in TRD will be entering Phase 2B/3 in Q2 2026 in EU+USA
